Opus Genetics (STU:R3X1) Marketable Securities : €0.00 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Opus Genetics's Marketable Securities for the quarter that ended in Dec. 2024 was €0.00 Mil.

Opus Genetics's annual Marketable Securities declined from Dec. 2022 (€0.05 Mil) to Dec. 2023 (€0.01 Mil) and declined from Dec. 2023 (€0.01 Mil) to Dec. 2024 (€0.00 Mil).

Opus Genetics Marketable Securities Historical Data

The historical data trend for Opus Genetics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics Marketable Securities Chart

Opus Genetics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

0.19

0.05

0.01

Opus Genetics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Marketable Securities	Get a 7-Day Free Trial															0.01	0.01	0.01	-	-

Opus Genetics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Opus Genetics (STU:R3X1) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Opus Genetics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Opus Genetics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Opus Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (STU:R3X1) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

IRD:USA R3X1:Germany

Address

8 Davis Drive, Suite 220, Durham, NC, USA, 27709

Website

https://www.opusgtx.com

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Opus Genetics Headlines

No Headlines